Do Institutional Investors Hate AGILE THERAPEUTICS INC (NASDAQ:AGRX)?

December 8, 2017 - By Hazel Jackson

 Do Institutional Investors Hate AGILE THERAPEUTICS INC (NASDAQ:AGRX)?


AGILE THERAPEUTICS INC (NASDAQ:AGRX) institutional sentiment decreased to 0.61 in 2017 Q2. Its down -0.39, from 1 in 2017Q1. The ratio fall, as 19 funds opened new and increased positions, while 31 trimmed and sold positions in AGILE THERAPEUTICS INC. The funds in our partner’s database now hold: 21.56 million shares, up from 21.41 million shares in 2017Q1. Also, the number of funds holding AGILE THERAPEUTICS INC in their top 10 positions was flat from 3 to 3 for the same number . Sold All: 15 Reduced: 16 Increased: 7 New Position: 12.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $162.04 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

The stock increased 3.95% or $0.18 during the last trading session, reaching $4.74. About 260,771 shares traded or 14.75% up from the average. Agile Therapeutics, Inc. (NASDAQ:AGRX) has declined 48.71% since December 8, 2016 and is downtrending. It has underperformed by 65.41% the S&P500.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on March, 14. They expect $-0.26 EPS, up 10.34 % or $0.03 from last year’s $-0.29 per share. After $-0.22 actual EPS reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 18.18 % negative EPS growth.

Proquest Associates Iv Llc holds 24.27% of its portfolio in Agile Therapeutics, Inc. for 5.06 million shares. Caxton Corp owns 1.62 million shares or 9.5% of their US portfolio. Moreover, Aisling Capital Llc has 1.16% invested in the company for 1.80 million shares. The Sweden-based Investor Ab has invested 0.92% in the stock. Cormorant Asset Management Llc, a Massachusetts-based fund reported 1.25 million shares.#img1#

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

Ratings analysis reveals 100% of Agile Therapeutics’s analysts are positive. Out of 4 Wall Street analysts rating Agile Therapeutics, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $8.0 while the high is $16. The stock’s average target of $10.50 is 121.52% above today’s ($4.74) share price. AGRX was included in 15 notes of analysts from December 30, 2015. The rating was maintained by H.C. Wainwright with “Buy” on Friday, July 28. The rating was maintained by Noble Financial with “Buy” on Thursday, November 9. The firm has “Buy” rating given on Monday, June 12 by Noble Financial. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, November 6 report. The company was maintained on Thursday, October 12 by H.C. Wainwright. The rating was maintained by Noble Financial on Friday, July 28 with “Buy”. The firm earned “Buy” rating on Tuesday, June 27 by Noble Financial. Noble Financial initiated the shares of AGRX in report on Wednesday, December 30 with “Buy” rating. The rating was maintained by RBC Capital Markets on Friday, July 14 with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, January 8.

More notable recent Agile Therapeutics, Inc. (NASDAQ:AGRX) news were published by: which released: “Agile Therapeutics: Is This ~$3.50 ‘Busted IPO’ Worthy Of Investment …” on September 05, 2017, also with their article: “Agile Therapeutics to Host First Analyst Day on October 10, 2017” published on October 02, 2017, published: “Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla┬«” on July 27, 2017. More interesting news about Agile Therapeutics, Inc. (NASDAQ:AGRX) were released by: and their article: “How a Birth Control Patch Hurt Agile Therapeutics’ Stock” published on January 04, 2017 as well as‘s news article titled: “Agile Therapeutics Reports Third Quarter 2017 Financial Results” with publication date: November 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.